CLearing Alzheimer's Disease Molecular Pathology Without Medications

Inclusion Criteria: * Informed Consent as documented by signature (Appendix Informed Consent Form), * age 40-80, * ≥5 years of education, * previous evidence of brain amyloidosis (assessed by PET, CSF, or blood-based biomarkers). Exclusion Criteria: * history of epilepsy; * clinically relevant visual or auditory diseases/deficits; * clinical diagnosis of dementia; * contraindication to amyloid-PET; * inability to undergo the procedures of the study, e.g. severe behavioral disturbances; * severe diseases: 1. Malignant neoplasm within 5 years, 2. Life threatening diseases, 3. Severe systemic diseases (e.g. kidney insufficiency, cardiac insufficiency, decompensated diabetes, decompensated metabolic diseases, decompensated hypothyroidism, uncontrolled autoimmune diseases); * the participation to a clinical trial involving potential Alzheimer's disease modifying therapies; * documented pregnancy or intention to become pregnant during the course of the study or breast feeding.